Rossana Roncato

PharmD PhD. Clinical Pharmacologist & Senior Researcher @UNIUD @CroAviano. #Personalizedmedicine #Pharmacogenetics #TDM #Implementation

[Richard Schilsky @rschilsky]

No longer any excuse for not doing PGx testing!
Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer https://t.co/sj7dbdC5Qm

[JAMA Network Open @JAMANetworkOpen]

Pharmacogenetic-informed therapy using DPYD and UGT1A1 testing for patients with gastrointestinal cancer reduces toxic effects and hospitalization costs while improving quality of life. https://t.co/fYaengnbu7

[Lorenzo Gerratana @LGerratana]

That’s a wrap! It’s been an inspiring time at Focus on TOP #FTOP24!

Thanks to our amazing faculty and to everyone who joined us, see you next year!

@puglisi_fabio @MCristofanill @UmbertoMalapel1 @vitti10 @LMalorni @gusbald @rossanaroncato @Marzia_DelRe

#Oncology #liquidbiopsy

[Centro di Riferimento Oncologico IRCCS @CroAviano]

Dal 21 al 23 febbraio il XXI '#Focus sul #carcinoma mammario' metterà a confronto gli specialisti.
📌Mercoledì 21, la sessione inaugurale - aperta al pubblico (anche in #streaming) - porrà al centro del dibattito l'importanza della comunicazione.
Info 👉 https://t.co/Q9C3T2d41N

[Centro di Riferimento Oncologico IRCCS @CroAviano]

😊Il CRO è tra i protagonisti del congresso #AIOM23. Diversi i professionisti del nostro istituto chiamati a presentare il proprio lavoro a Roma. Da segnalare anche il premio al corto ‘D’un tratto’ progettato da Fabio Puglisi.
Scopri di più 👉 https://t.co/MxGZL06qRV

[Lorenzo Gerratana @LGerratana]

Average Cmin (steady-state trough concentration) in normal-low BMI was 77.95 ng/ml, while in BMI high it was 62.50 ng/ml.

The 25% increase in Cmin suggests the impact of drug sequestration within adipose tissue, a crucial given palbociclib's high volume of distribution

🧵5/5

[Lorenzo Gerratana @LGerratana]

High BMI was linked with fewer dose-limiting hematologic #toxicities, enabling a higher dose intensity

A higher dose intensity resulted in better PFS

Plasma drug monitoring was also performed

🧵4/5

#TDM #PrecisionMedicine #DrugMonitoring #Pharmacology

[Lorenzo Gerratana @LGerratana]

A recent prospective study delved into baseline pharmacological profiling in patients treated for metastatic #BreastCancer using #palbociclib

🧵3/5

https://t.co/quyIncmpAt

#MBC

[Lorenzo Gerratana @LGerratana]

No survival differences across #BMI categories by treatment arm.

❓Hypothesis: lower incidence of adverse events linked to a larger distributional volume of the drug

‼️ No #pharmacokinetics data were available in the context of the trial.

🧵2/5

https://t.co/VMjVnmUMFu

[Lorenzo Gerratana @LGerratana]

Pfeiler et al.'s recent analysis of the #PALLAS trial uncovered interesting data about the impact of BMI on palbociclib in early #BreastCancer:

Higher BMI linked to reduced neutropenia risk.

Lower treatment discontinuation rates in patients with high BMI

🧵1/5

[Lorenzo Gerratana @LGerratana]

Body mass index impacts #AdverseEvents and drug plasma concentration in patients with #BreastCancer: should dose intensity be included in the #palbociclib equation? a letter ✉️ (👇below) and a thread🧵

@rossanaroncato @puglisi_fabio

https://t.co/RSxLW99Bo8

[Rossana Roncato @rossanaroncato]

🧬#Pharmacogenetic variants impacting safety profiles of CDK4/6 Inhibitors in #MetastaticBreastCancer!

🩸 ABCB1 T-T-T(A) and CYP3A4*22 carriers:
⬆️ Risk of early DLTs

📌 ABCB1 T-T-T(A) carriers have higher #ribociclib Ctrough

@LGerratana @puglisi_fabio
https://t.co/DAdwBdWME6

[Lorenzo Gerratana @LGerratana]

Attending the Italian Breast Group annual meeting is always a great opportunity to discuss ongoing studies and share new trial ideas with awesome friends. Now it’s time to make all our projects happen! 💪 #CTC #ctDNA #BreastCancer #liquidbiopsy #PrecisionMedicine #GIM2023

[Rossana Roncato @rossanaroncato]

Honored to be awarded the first poster prize in Pharmacogenomics during the #WCP2023! Huge thanks to the @BritPharmSoc for this award and to all the co-authors who made this work possible!
@LGerratana @puglisi_fabio @JesseSwen @HenkJGuchelaar

[British Pharmacological Society @BritPharmSoc]

Over 1,100 abstracts were selected to be presented as posters throughout #WCP2023. Please join us in congratulating the winners and runners-up of the Poster Prizes: https://t.co/jThLgwsneh
🎉👏👏👏

#PosterPrizes #Pharmacology #ClinicalPharmacology #Therapeutics #Abstracts

[Lorenzo Gerratana @LGerratana]

Therapeutic #drug monitoring as a crucial piece of #PrecisionMedicine in metastatic #BreastCancer. BMI<25 was associated to an increased concentration of #palbociclib resulting in higher toxicities and lower dose intensity linked to worse PFS ⁩#bcsm https://t.co/iUxByKZmet

[Lorenzo Gerratana @LGerratana]

#ESR1 mutations in the docking site of Selective Estrogen Receptor Degraders and Modulators #SERD differentially impact on drug affinity across agents. Check today's #SABCS22 spotlight poster discussion. Integrating #ctDNA and #pharmacodynamics. #PrecisionMedicine #BreastCancer

[SIF @SIFfarmacologia]

Questa mattina, il Prof. Franco Locatelli, Presidente del Consiglio Superiore di Sanità e tra i più eminenti esperti di patologie ematologiche pediatriche, è intervenuto nel corso del Seminario per Dottorandi SIF di fronte a una platea di giovani #farmacologi.
#SIF2022

[Lorenzo Gerratana @LGerratana]

How to integrate CDK4/6 inhibitors with a #personalized pharmacological approach in #BreastCancer patients. The key to #PrecisionMedicine is the best #treatment for each target tailored around each person #MBC #bcsm Great project at ⁦⁦@CroAviano⁩ https://t.co/6bKnqwi75j

[Metabolites MDPI @MetabolitesMDPI]

Welcome our new guest editors team🔬Dr. Valentina Manzo, Dr. Federica Mannino, Dr. Stefania Crucitta and Dr. Rossana Roncato, leading the Special Issue 📗"#Polymorphisms of #Drug #Metabolizing Enzymes and Transporters"📢Open for submissions now!

https://t.co/4FBITFkJ2K

[Lorenzo Gerratana @LGerratana]

Looking forward to showing exciting new data on the interplay between #ESR1 and #PIK3CA codon variants and oncogenic pathways in #Metastatic #BreastCancer through #ctDNA characterization at the #SABCS21 Spotlight Session #bcsm #MBC #PrecisionMedicine #LiquidBiopsy @CtcLaboratory